Regulatory Update

Bend, Ore. – September 19, 2026 -- Amazon Web Services has published MSP Validation Checklist (VCL) 8.0, a revised standard requiring managed service providers to prove AI-driven delivery capabilities to earn and maintain AWS MSP validation, cloud operations firm Platformr said.

AWS overhauls 61 controls to embed AI across every requirement

Of the standard's 61 total controls, 24 are entirely new, covering agentic AI platform and agent lifecycle governance, a Responsible AI framework for data governance and prompt injection prevention, agentic Zero Trust and blast-radius containment, and GenAI observability tracking sessions, traces, drift and cost. The update also mandates operational toil measurement, an AI transformation roadmap with industry vertical specialization, and new Forward Deployed Engineer and AI Practice Lead roles.

Washington – September 19, 2026 -- More than 20,100 Americans signed a petition in just four days demanding Congress reauthorize the Accelerating Access to Critical Therapies (ACT) for ALS law before its September 19, 2026 expiration date.

Petition drive targets key congressional committees ahead of deadline

The campaign, organized by advocacy group I AM ALS during its annual Week of Impact, directs the petition at Senate HELP Committee and House Energy and Commerce Committee leadership. Signatories include patients living with ALS, caregivers, researchers, and clinicians who rely on programs the law established.

Singapore – September 19, 2026 -- KELLS' AI Dental Scan has become the first AI-powered dental screening tool registered as a Class B medical device by Singapore's Health Sciences Authority (HSA) for direct consumer use, the company announced.

HSA registration validates KELLS' proprietary AI for at-home dental screening

The clearance allows users to capture smartphone images of their teeth, which KELLS' AI then analyzes to flag potential oral health concerns and indicate when professional dental care may be warranted. The registration marks a regulatory first for consumer-facing dental AI tools in Singapore and supports the company's expansion in the market.

Santa Clarita, Calif. – September 19, 2026 -- Datalink Networks has completed its SOC 2 Type 2 examination as of September 19, 2026, providing independent verification of the security controls underpinning its IT managed and consulting services.

Audit confirms controls met AICPA Security Trust Services Criteria

The examination, conducted by compliance assessor A-LIGN, evaluated Datalink's security, risk management, access controls, monitoring, incident response, and change management practices. Auditors reviewed controls operating from September 19, 2026, through September 19, 2026, and found them suitably designed and operating effectively throughout the period.

Atlanta – – September 19, 2026 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq's minimum stockholders' equity rule, ending a listing threat that began in March 2026.

Nasdaq confirms Alzamend's equity now exceeds required threshold

Nasdaq's Listing Qualifications Staff issued a notification letter dated September 19, 2026, confirming Alzamend satisfies Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Alzamend's Quarterly Report on Form 10-Q for the quarter ended September 19, 2026, filed with the SEC on September 19, 2026, showed stockholders' equity of $5,802,680, more than double the required minimum.

Secaucus, N.J. – September 19, 2026 -- A new national survey commissioned by Quest Diagnostics (NYSE: DGX) finds that 75% of 1,024 registered voters surveyed consider diagnostic lab testing "very important" to their care, with a bipartisan majority pressing Congress to pass the RESULTS Act before scheduled Medicare payment cuts take effect September 19, 2026.

83% of voters relied on a lab test in the past two years to guide a medical decision

The survey found 96% of registered voters view diagnostic lab tests as important to their or their family's care, while 88% expressed concern if Medicare lab payment rates were set too low. Half of respondents said Medicare seniors, rural communities, and people managing cancer or chronic disease would be hurt most if the cuts take effect.

New York – September 19, 2026 -- Eucalyptus Resources Opportunities Fund 1, LP said its slate of four director nominees at TNR Gold Corp. (TSXV: TNR) has secured support from over 45% of shares ahead of a September 19, 2026, 9:00 p.m. Eastern Time proxy voting deadline, up from roughly 43% disclosed just two days earlier.

Rockville, Md. – September 19, 2026 -- Turning Point Global Solutions (TurningPoint) has been appraised at Maturity Level 3 for Services under ISACA's Capability Maturity Model Integration (CMMI) framework for the fourth consecutive time, an assessment conducted by Primvis Inc.

Fourth Level 3 appraisal reinforces process discipline across federal and commercial contracts

The Level 3 rating confirms TurningPoint's service delivery processes are formally defined, documented in standards, procedures and tools, and consistently applied across engagements. The appraisal complements the company's existing Maturity Level 5 rating for Development, the highest tier in the CMMI model, which requires organizations to continually refine processes using quantitative performance data.

Valby, Denmark – – September 19, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.

MHLW clears the only IV CGRP-targeted migraine preventive on the market

Eptinezumab remains the sole intravenous CGRP-targeted therapy approved for migraine prevention, now available in more than 30 markets worldwide following the Japanese clearance. The drug was first approved by the U.S. FDA in February 2020, followed by the European Commission in January 2022 and, most recently, South Korea.

Washington, D.C. – – September 19, 2026 -- Advocates for limb-girdle muscular dystrophy (LGMD) held more than 60 meetings with congressional offices this week, representing patients from over 20 states, as part of The Speak Foundation's LGMD Day on the Hill.

No FDA-approved treatment exists for LGMD despite scientific progress

LGMD is a group of rare genetic diseases causing progressive muscle weakness, and no FDA-approved treatment currently targets the condition. Advocates urged lawmakers to increase federal investment in LGMD research, expand access to Department of Defense research funding, and push for clearer, more consistent regulatory pathways for rare-disease treatments.